Johnson & Johnson 경영진
경영진 기준 점검 2/4
Johnson & Johnson CEO는 Joaquin Duato, Jan2022 에 임명되었습니다 의 임기는 4.58 년입니다. 총 연간 보상은 $32.76M, 4.9% 급여 및 95.1% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $79.78M 가치에 해당하는 회사 주식의 0.013% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 4.6 년과 6.2 년입니다.
핵심 정보
Joaquin Duato
최고경영자
US$32.8m
총 보수
| CEO 급여 비율 | 4.88% |
| CEO 재임 기간 | 4.6yrs |
| CEO 지분 보유율 | 0.01% |
| 경영진 평균 재임 기간 | 4.6yrs |
| 이사회 평균 재임 기간 | 6.2yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Jul 31
JNJ: New Drug Cycle And Talc Settlement Progress Will Balance Policy Risks
Johnson & Johnson's analyst fair value estimate has been raised from $252.87 to $270.59, reflecting higher Street price targets tied to recent Q2 beats, updated guidance, progress on new medicines, and greater clarity around talc litigation exposure. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of enthusiasm around execution on new medicines and MedTech, alongside measured caution on policy and competitive pressures.
내러티브 업데이트 • Jul 17
JNJ: Oncology Focus And New Medicines Will Drive Confidence Through 2026
Analysts raised the Johnson & Johnson fair value estimate to $305 from $265 after a series of price target increases tied to a recent quarterly beat, higher full year guidance, and growing confidence in the company's new medicines and projected revenue trajectory through 2026. Analyst Commentary Recent Street research around Johnson & Johnson has turned more constructive, with a cluster of upgrades and higher price targets following the latest quarterly results and revised guidance.Seeking Alpha • Jul 15
Johnson & Johnson Q2: Solid (If Not Spectacular) Performance Satisfies Wall Street
Summary Johnson & Johnson delivered strong Q2 2026 results, with 6.6% annual revenue growth and robust performance across Pharma and MedTech divisions. JNJ maintains mid-to-high single digit revenue growth, a portfolio of 15+ "blockbuster" drugs, and a solid pipeline, supporting its blue-chip status. I am downgrading JNJ from Strong Buy to Buy due to valuation normalization and tempered forward share price expectations, despite continued operational strength. JNJ offers stable dividends (>2% yield), high profitability (27.5% operating margin in 2025), and remains a reliable 'buy and hold' within Big Pharma. Read the full article on Seeking Alpha
내러티브 업데이트 • Jul 03
JNJ: Drug Pipeline Optimism Will Face Pressure From Medicare Pricing Rules
For Johnson & Johnson, the analyst price target has been revised higher. The updated fair value estimate has moved from about $181.77 to $212.24 as analysts factor in refreshed revenue growth assumptions, slightly adjusted discount and margin inputs, and a higher future P/E in light of recent research pointing to ongoing new drug momentum and broadly supportive earnings expectations.분석 기사 • Jun 21
Johnson & Johnson (JNJ) Stock Could Be 7.3% Undervalued Based On Its Pharma And MedTech Focus
Johnson & Johnson (JNJ) is back in focus after recent share price weakness, with the stock down 2% over the past month and about 3% over the past 3 months, prompting fresh interest in its valuation. See our latest analysis for Johnson & Johnson. Despite the recent share price weakness over the past week and quarter, Johnson & Johnson’s year to date share price return of 10.15% and 1 year total shareholder return of 56.28% point to momentum that has been positive overall. If this kind of move...내러티브 업데이트 • Jun 19
JNJ: Future Drug Cycle And Dividend Strength Will Balance Policy And Legal Risks
Analysts have raised the Johnson & Johnson price target to $265 from $252, reflecting increased confidence in the company’s new drug momentum and product cycle, while also considering ongoing policy and partnership risks highlighted in recent research. Analyst Commentary Recent Street research around Johnson & Johnson highlights a mix of enthusiasm about the company’s new drug pipeline and product cycle, alongside fresh policy questions and selected partnership headwinds that investors should factor into expectations for execution and valuation.내러티브 업데이트 • Jun 04
JNJ: Future Drug Cycle Momentum Is Expected To Drive Returns
Analysts have nudged their price targets for Johnson & Johnson higher, with recent revisions clustering in the mid to high $260s and up to $280, as they point to strong new drug momentum and product cycle strength as key drivers supporting slightly higher revenue growth expectations and a rich future P/E framework. Analyst Commentary Recent research remains broadly constructive on Johnson & Johnson, with several bullish analysts citing product cycle momentum, new drug contributions, and a supportive P/E setup.내러티브 업데이트 • May 14
JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns
Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.내러티브 업데이트 • Apr 24
JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks
The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.내러티브 업데이트 • Apr 09
JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience
Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.내러티브 업데이트 • Mar 25
JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience
Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.새로운 내러티브 • Mar 18
Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Mar 11
JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty
Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.내러티브 업데이트 • Feb 25
JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk
The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.내러티브 업데이트 • Feb 10
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance
Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 28 2026 | n/a | n/a | US$21b |
| Mar 29 2026 | n/a | n/a | US$21b |
| Dec 28 2025 | US$33m | US$2m | US$27b |
| Sep 28 2025 | n/a | n/a | US$25b |
| Jun 29 2025 | n/a | n/a | US$23b |
| Mar 30 2025 | n/a | n/a | US$22b |
| Dec 29 2024 | US$24m | US$2m | US$14b |
| Sep 29 2024 | n/a | n/a | US$15b |
| Jun 30 2024 | n/a | n/a | US$16b |
| Mar 31 2024 | n/a | n/a | US$17b |
| Dec 31 2023 | US$28m | US$2m | US$13b |
| Oct 01 2023 | n/a | n/a | US$12b |
| Jul 02 2023 | n/a | n/a | US$12b |
| Apr 02 2023 | n/a | n/a | US$11b |
| Jan 01 2023 | US$13m | US$1m | US$16b |
| Oct 02 2022 | n/a | n/a | US$18b |
| Jul 03 2022 | n/a | n/a | US$17b |
| Apr 03 2022 | n/a | n/a | US$20b |
| Jan 02 2022 | US$14m | US$1m | US$18b |
| Oct 03 2021 | n/a | n/a | US$18b |
| Jul 04 2021 | n/a | n/a | US$18b |
| Apr 04 2021 | n/a | n/a | US$15b |
| Jan 03 2021 | n/a | n/a | US$15b |
| Sep 27 2020 | n/a | n/a | US$17b |
| Jun 28 2020 | n/a | n/a | US$15b |
| Mar 29 2020 | n/a | n/a | US$17b |
| Dec 29 2019 | US$13m | US$970k | US$15b |
보상 대 시장: Joaquin의 총 보수(USD32.76M)는 US 시장에서 비슷한 규모 기업의 평균(USD14.39M)보다 높습니다.
보상과 수익: Joaquin의 보상은 20% 이상 증가했지만 지난 1년 동안 회사 수익은 20% 이상 감소했습니다.
CEO
Joaquin Duato (63 yo)
4.6yrs
재임 기간
US$32,758,111
보수
Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Chairman | 4.6yrs | US$32.76m | 0.013% $ 79.8m | |
| Executive VP & CFO | 8.1yrs | US$14.41m | 0.0035% $ 22.1m | |
| Executive Vice President of Innovative Medicine and R&D | 3.3yrs | US$12.21m | 0.0010% $ 6.4m | |
| Executive VP & Worldwide Chairman of MedTech | 2.8yrs | US$9.34m | 0.0011% $ 6.8m | |
| Controller & Chief Accounting Officer | 6.7yrs | 데이터 없음 | 0.0010% $ 6.4m | |
| Executive VP & Chief Information Officer | 6.8yrs | 데이터 없음 | 0.0011% $ 6.7m | |
| Vice President of Investor Relations | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Compliance Officer | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief Legal Officer | 3.8yrs | 데이터 없음 | 0.00071% $ 4.4m | |
| Executive VP & Chief HR Officer | no data | 데이터 없음 | 0.00082% $ 5.1m | |
| Group Chairman of MD&D Business - EMEA | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP and Chief Technical Operations & Risk Officer | 8.1yrs | 데이터 없음 | 0.0048% $ 29.7m |
4.6yrs
평균 재임 기간
59yo
평균 나이
경험이 풍부한 관리: JNJ의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.6 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Chairman | 4.6yrs | US$32.76m | 0.013% $ 79.8m | |
| Director | less than a year | US$59.13k | 0.000080% $ 499.8k | |
| Independent Director | 6.7yrs | US$367.55k | 0.00021% $ 1.3m | |
| Lead Independent Director | 7.3yrs | US$413.00k | 0.00012% $ 749.7k | |
| Independent Director | 3.5yrs | US$344.00k | 0.000010% $ 62.5k | |
| Independent Director | 12.8yrs | US$330.00k | 0% $ 0 | |
| Independent Director | 11.2yrs | US$375.00k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$370.00k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$347.16k | 0.000010% $ 62.5k | |
| Independent Director | 6.7yrs | US$355.00k | 0.000040% $ 249.9k | |
| Director | 1.1yrs | US$62.50k | 데이터 없음 | |
| Independent Director | 5.7yrs | US$350.00k | 0% $ 0 |
6.2yrs
평균 재임 기간
63.5yo
평균 나이
경험이 풍부한 이사회: JNJ의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.2 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/10 06:54 |
| 종가 | 2026/08/10 00:00 |
| 수익 | 2026/06/28 |
| 연간 수익 | 2025/12/28 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Johnson & Johnson는 53명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Lee Hambright | Bernstein |